{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:00:05Z","timestamp":1780941605753,"version":"3.54.1"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2670958","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:29:20Z","timestamp":1780939760000},"page":"1526-1536","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Modeling the cost-effectiveness of the COVID-19 mRNA-1273 vaccine in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Kelly","family":"Fust","sequence":"first","affiliation":[{"name":"Quadrant Health Economics, Inc","place":["Cambridge, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Kohli","sequence":"additional","affiliation":[{"name":"Quadrant Health Economics, Inc","place":["Cambridge, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Cartier","sequence":"additional","affiliation":[{"name":"Quadrant Health Economics, Inc","place":["Cambridge, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Van de Velde","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keya","family":"Joshi","sequence":"additional","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"United States Center for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States; 2025. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html?CDC_AA_refVal=https%3A\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html."},{"key":"e_1_3_3_3_1","unstructured":"ModernaTX I. SPIKEVAX full prescribing information; 2025."},{"key":"e_1_3_3_4_1","unstructured":"United States Food and Drug Administration. COVID-19 vaccines (2025-2026 formula) for use in the United States beginning in fall 2025; 2025. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025."},{"key":"e_1_3_3_5_1","unstructured":"Pfizer\/BioNTech. COMIRNATY full prescribing information; 2025."},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Fust K Kohli M Joshi K. Modeling the anticipated public health benefits of the next-generation COVID-19 mRNA-1283 vaccine: an interim U.S. Population-level impact assessment (pre-print); 2025. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.09.26.25336704v1.","DOI":"10.1101\/2025.09.26.25336704"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Fust K Km Joshi K. Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States; 2025. Available from: https:\/\/www.medrxiv.org\/content\/10.64898\/2025.12.01.25341380v1.","DOI":"10.64898\/2025.12.01.25341380"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.23688"},{"key":"e_1_3_3_9_1","unstructured":"Centers for Disease Control and Prevention. Updates to COVID-19 epidemiology. Advisory Committee on Immunization Practices; 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-09-18-19\/02-Srinivasan-covid-508.pdf."},{"key":"e_1_3_3_10_1","unstructured":"University of Michigan COVID-19 Vaccination Modeling Team. Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine. Presentation to the Advisory Committee on Immunization Practices; 2024."},{"key":"e_1_3_3_11_1","unstructured":"Center for Disease Control and Prevention. Vaccines & immunizations. Adult immunization schedule by age (Addendum updated August 7 2025); 2025. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/adult-age.html."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7349a2"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1792"},{"key":"e_1_3_3_14_1","unstructured":"ASPE Office of Science and Data Policy. HHS standard values for regulatory analysis; 2025. Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/639756a60fbe7e51786bcec176ad52f1\/Standard-RIA-Values-2025.pdf."},{"key":"e_1_3_3_15_1","unstructured":"United Nations Department of Economic and Social Affairs (Population Division). World Population Prospects 2024 Online Edition; 2024. Available from: https:\/\/population.un.org\/wpp\/downloads?folder=Standard%20Projections&group=Population."},{"key":"e_1_3_3_16_1","unstructured":"Food and Drug Administration. MNEXSPIKE; 2025. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/mnexspike."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9855"},{"key":"e_1_3_3_18_1","unstructured":"Panagiotakopoulos L. Use of 2025\u20132026 COVID-19 vaccines: work group considerations. Presentation to the Advisory Commitee on Immunization Practices; 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/05-Panagiotakopoulos-COVID-508.pdf."},{"key":"e_1_3_3_19_1","article-title":"Evaluating the effectiveness of 2024-2025 seasonal mRNA-1273 vaccination against COVID-19-associated hospitalizations and medically attended COVID-19 among adults aged \u226518 years in the United States","author":"Wilson A","year":"2025","unstructured":"Wilson A, Bogdanov A, Zheng Z, et al. Evaluating the effectiveness of 2024-2025 seasonal mRNA-1273 vaccination against COVID-19-associated hospitalizations and medically attended COVID-19 among adults aged \u226518 years in the United States. medRxiv. 2025.","journal-title":"medRxiv"},{"key":"e_1_3_3_20_1","unstructured":"MacNeil A. Updates to COVID-19 vaccine effectiveness. Presentation to the Advisory Committee on Immunization Practices; 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/03-MacNeil-COVID-508.pdf"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.13.24313632"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00936-z"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00409-1"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-001074"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5258507"},{"key":"e_1_3_3_26_1","unstructured":"Center for Disease Control and Prevention. Vaccines for children program. Current CDC vaccine price list; 2025. Available from: https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html."},{"key":"e_1_3_3_27_1","unstructured":"University of Michigan COVID-19 Vaccination Modeling Team. Economic analysis of COVID-19 vaccination; 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/05-COVID-Prosser-508.pdf."},{"key":"e_1_3_3_28_1","unstructured":"Centers for Medicare & Medicaid Services. National physician fee schedule relative value file October release; 2025. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician\/pfs-relative-value-files\/rvu25d-0."},{"key":"e_1_3_3_29_1","unstructured":"Centers for Medicare & Medicaid Services. Vaccine pricing; 2024. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/vaccine-pricing."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01128-z"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.7179"},{"key":"e_1_3_3_32_1","unstructured":"Havers FP. COVID-19\u2013Associated Hospitalizations\u2014COVID-NET April 2025 Update. Presentation to the Advisory Committee on Immunization Practices; 2025. Available from: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/03-Havers-COVID-508.pdf."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2670958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:29:27Z","timestamp":1780939767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2670958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2670958"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2670958","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}